OncoMatch/Clinical Trials/NCT06577532
Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors
Is NCT06577532 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies multiple treatments including ABO2102 and Toripalimab for pancreatic neoplasms.
Treatment: ABO2102 · Toripalimab — The purpose of this study is to evaluate the safety, immunogenicity, pharmacodynamics, as well as preliminary efficacy of KRAS neoantigen mRNA vaccine (ABO2102) alone and in combination with toripalimab (anti-PD-1 monoclonal antibody) among participants with KRAS-mutated advanced pancreatic cancer and other solid tumors. The trial includes dose escalation (Part I) and dose expansion(Part II) parts.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Pancreatic Cancer
Tumor Agnostic
Biomarker criteria
Required: KRAS targeted mutant
Harboring at least one of the targeted KRAS mutants
Disease stage
Metastatic disease required
advanced solid tumors
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy
disease has progressed or being intolerant to relevant treatments during or following at least one line of systemic treatment
Cannot have received: KRAS cancer vaccine
Received KRAS cancer vaccine before
Lab requirements
Blood counts
sufficient organ function
Kidney function
sufficient organ function
Liver function
sufficient organ function
Sufficient organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06577532 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior KRAS cancer vaccine disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS targeted mutant is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages